IRIS - Res&Arch Institutional Research Information System - Research & Archive

PORCELLATI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.660
EU - Europa 2.832
AS - Asia 2.705
SA - Sud America 435
AF - Africa 60
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.565
SG - Singapore 1.306
IT - Italia 461
CN - Cina 391
IE - Irlanda 389
RU - Federazione Russa 377
SE - Svezia 347
BR - Brasile 342
UA - Ucraina 320
HK - Hong Kong 293
VN - Vietnam 268
DE - Germania 239
FR - Francia 181
FI - Finlandia 155
GB - Regno Unito 113
BD - Bangladesh 90
IN - India 75
ES - Italia 68
KR - Corea 58
CA - Canada 40
AT - Austria 37
TR - Turchia 37
PL - Polonia 36
AR - Argentina 32
MX - Messico 31
ZA - Sudafrica 30
IQ - Iraq 27
JP - Giappone 27
NL - Olanda 24
UZ - Uzbekistan 23
CZ - Repubblica Ceca 19
PK - Pakistan 19
AU - Australia 16
PH - Filippine 14
VE - Venezuela 14
BE - Belgio 13
SA - Arabia Saudita 13
CH - Svizzera 12
EC - Ecuador 12
ID - Indonesia 12
CO - Colombia 9
PE - Perù 9
RO - Romania 7
TT - Trinidad e Tobago 7
AZ - Azerbaigian 6
BO - Bolivia 6
JO - Giordania 6
LT - Lituania 6
MA - Marocco 6
EG - Egitto 5
JM - Giamaica 5
KE - Kenya 5
NP - Nepal 5
DK - Danimarca 4
GR - Grecia 4
IL - Israele 4
MY - Malesia 4
OM - Oman 4
PS - Palestinian Territory 4
PY - Paraguay 4
UY - Uruguay 4
DO - Repubblica Dominicana 3
EU - Europa 3
LB - Libano 3
RS - Serbia 3
TH - Thailandia 3
TN - Tunisia 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AO - Angola 2
BB - Barbados 2
BW - Botswana 2
CL - Cile 2
CR - Costa Rica 2
EE - Estonia 2
GE - Georgia 2
HU - Ungheria 2
NZ - Nuova Zelanda 2
PA - Panama 2
SI - Slovenia 2
XK - ???statistics.table.value.countryCode.XK??? 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
DZ - Algeria 1
ET - Etiopia 1
FJ - Figi 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
IM - Isola di Man 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
NE - Niger 1
Totale 9.707
Salva come PNG Salva come JPEG
Città #
Singapore 950
Chandler 474
San Jose 425
Dublin 389
Hong Kong 290
Ashburn 234
San Mateo 224
Boardman 177
Jacksonville 160
Santa Clara 135
Moscow 129
Altamura 112
Medford 109
Princeton 109
Lauterbourg 103
Beijing 94
Munich 93
Wilmington 92
Perugia 91
Lawrence 80
Ann Arbor 79
Dong Ket 76
New York 70
Los Angeles 59
Seoul 58
Andover 53
Ho Chi Minh City 53
Helsinki 52
Valencia 50
Rome 45
The Dalles 41
Des Moines 39
Hanoi 37
Frankfurt am Main 33
São Paulo 28
Saint Petersburg 27
Brooklyn 25
Chicago 25
Piscataway 25
Woodbridge 23
Warsaw 22
Norwalk 21
Nuremberg 21
Falls Church 20
Tokyo 20
Turku 20
Milan 18
Orem 18
Amsterdam 16
Tashkent 16
Vienna 16
Amelia 15
Brno 14
Izmir 13
Baghdad 12
Brussels 12
Da Nang 12
Falkenstein 12
London 12
Stockholm 12
Toronto 12
Mumbai 11
San Francisco 11
Ankara 9
Atlanta 9
Boston 9
Dallas 9
Denver 9
Foligno 9
Johannesburg 9
Poplar 9
Porto Alegre 9
Belo Horizonte 8
Bexley 8
Dhaka 8
Istanbul 8
Montreal 8
Phoenix 8
San Paolo di Civitate 8
Auburn Hills 7
Council Bluffs 7
Guayaquil 7
Houston 7
Hải Dương 7
Mexico City 7
Redmond 7
Columbus 6
Curitiba 6
Durban 6
Fremont 6
Goiânia 6
Guangzhou 6
Haiphong 6
Hyderabad 6
Juárez 6
Melbourne 6
Rio de Janeiro 6
Riyadh 6
Shanghai 6
Amman 5
Totale 5.993
Salva come PNG Salva come JPEG
Nome #
Ipoglicemia da iperinsulinismo organico: un caso di nesidioblastosi dell’adulto. 215
Adrenaline vs glucagon in the primacy of glucose counterregulation 173
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 157
Hypoglycemia 151
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 150
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 134
Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study 127
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 126
EFFECT OF PYRIDOXAL 5'-PHOSPHATE AND VALPROICACID ON PHOSPHOLIPID SYNTHESIS INNEUROBLASTOMA NA 124
A novel surrogate index for hepatic insulin resistance. 124
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 124
Administration of Neutral Protamine Hagedorn insulin at bedtime versus dinner in Type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control: a randomized, controlled trial. 124
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 119
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 119
Awareness, identification and prevention of insulin injection-associated lipodystrophies 119
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 118
Cognitive function in hypoglycaemia 116
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 116
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 115
Ipoglicemia: implicazioni cliniche e impatto sulla salute 112
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 111
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 111
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 110
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 107
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 107
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 107
[Usefulness of plantar pressure measurement for the prevention and treatment of neuropathic diabetic foot]. 106
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 103
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 101
Alternate splicing in human Na+-MI cotransporter gene yelds differentially regulated trasport isoforms 100
Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. 100
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 99
EPIDEMIOLOGICAL SURVEY FOR THE DETECTION OF NON–TRAUMATIC LOWER EXTREMITY AMPUTATIONS IN DIABETIC PATIENTS IN THE UMBRIA REGION (ITALY). 99
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 96
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin 96
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. 94
Body composition and common carotid artery remodeling in a healthy population 94
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 94
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 93
Glucagon: the effects of its excess and deficiency on insulin action 93
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 93
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 93
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 92
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 92
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 91
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 89
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 88
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 88
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 86
ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role? 86
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 86
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 83
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 83
Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. 82
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 82
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 81
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 81
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 80
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 79
Obesity and carotid artery remodeling 79
One hour post-load plasma glucose and 3 year risk of worsening fasting and 2 hour glucose tolerance in the RISC cohort 79
Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure 78
The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study 76
Responses to hypoglycemia in diabetic autonomic neuropathy. 75
Low levels of unmodified insulin glargine in plasma of people with type 2 diabetes requiring high doses of basal insulin 73
Quando “i conti non tornano” (Caso clinico) G It Diabetol Metab 26:172-175 72
Effect of sedentary behaviour and vigorous physical activity on segment-specific carotid wall thickness and its progression in a healthy population 72
Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage 71
Insulin therapy and hypoglycemia: the size of the problem 71
Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. 71
Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. 71
Recovery and prevention of hypoglycaemia unawareness in Type 1 diabetes mellitus 70
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. 69
Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study. Response to Banarer. 69
The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women 69
Modification and validation of the triglyceride-to-HDL cholesterol ratio as a surrogate of insulin sensitivity in white juveniles and adults without diabetes mellitus: The single point insulin sensitivity estimator (SPISE) 68
Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk 68
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 66
Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes. 66
Mechanisms of arterial hypotension after therapeutic dose of subcutaneous insulin in diabetic autonomic neuropathy. 65
Glucagon as a therapeutic approach to severe hypoglycemia: After 100 years, is it still the antidote of insulin? 65
Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. 64
INSULIN SENSITIVITY IN TYPE 2 DIABETIC PATIENTS IS DIFFERENT BETWEEN GLUCOSE AND PROTEIN METABOLISM 63
How to accurately establish pharmacokinetics/ pharmacodynamics of long- Acting insulins in humans: Relevance to biosimilar insulins 63
Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology 63
Impact of family history on relations between insulin resistance, LDL cholesterol and carotid IMT in healthy adults 61
Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial 60
L’insulina biosimilare è “clinicamente uguale” all’originator, ma… 60
The physiological basis of insulin therapy in people with diabetes mellitus 60
Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways 60
Gli Analoghi dell’Insulina ad Azione Ritardo: dalla storia di ieri alle opzioni di oggi 59
Shape of the OGTT glucose curve and risk of impaired glucose metabolism in the EGIR-RISC cohort 59
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes mellitus. 58
The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: Innocent bystander or partner in crime? 57
Real-time continuous glucose monitoring decreases the risk of severe hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia 57
Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials 57
Pharmacokinetics and pharmacodynamics of basal insulins. 56
Metabolic effects of an SGLT2 inhibitor (Dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes. Diabetes care 2020;43:2128– 2136 55
Ipoglicemia: Implicazioni cliniche e impatto sulla salute 54
Renal function markers and insulin sensitivity after 3 years in a healthy cohort, the EGIR-RISC study 54
Totale 9.002
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.626
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.626
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021102 0 0 0 0 0 0 0 0 0 0 0 102
2021/2022839 20 156 21 59 20 14 8 271 17 25 102 126
2022/20231.510 116 287 17 126 115 191 2 69 527 6 43 11
2023/2024658 36 76 35 11 5 7 121 2 44 28 147 146
2024/20251.624 25 157 45 98 264 37 61 146 319 108 214 150
2025/20263.755 262 228 187 359 506 267 691 215 519 300 123 98
Totale 9.948